Completing the study also satisfied an FDA requirement for the upcoming Phase 3 trials of AD04. Also Read: EXCLUSIVE: Adial ...

Adial Pharmaceuticals (ADIL) announced that it has completed a pharmacokinetics, PK, study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, and ...

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effectMarks ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 78,900 shares, a ...

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage ...

GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...

Short interest in Adial Pharmaceuticals Inc (NASDAQ:ADIL) decreased during the last reporting period, falling from 77.82K to 51.17K. This put 0.82% of the company's publicly available shares short.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of ...